Document is current
Any future updates will be listed below
-
Authors
Sun, Duanchen
Guan, Xiangnan
Moran, Amy E. https://orcid.org/0000-0003-1952-7737
Wu, Ling-Yun https://orcid.org/0000-0001-9487-0215
Qian, David Z.
Schedin, Pepper https://orcid.org/0000-0003-4244-987X
Dai, Mu-Shui
Danilov, Alexey V.
Alumkal, Joshi J.
Adey, Andrew C. https://orcid.org/0000-0001-7648-8717
Spellman, Paul T. https://orcid.org/0000-0002-4810-0022
Xia, Zheng https://orcid.org/0000-0003-3364-8324
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA207377, 1R01CA244576, 1R01CA251245, P50 CA186786, P50 CA186786-07S1)
U.S. Department of Defense (W81XWH-16-1-0597)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM124704)
U.S. Department of Health & Human Services | NIH | U.S. National Library of Medicine (5K01LM012877)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1R21HL145426)
The Medical Research Foundation of Oregon
- License Information
-
More Information
Article History
Received: 5 June 2020
Accepted: 10 September 2021
First Online: 11 November 2021
Competing interests
: A.E.M. discloses receipt of a sponsored research agreement from AstraZeneca. A.V.D. reports consultancy from Abbvie, Beigene, Celgene, Curis, Janssen, Karyopharm, Nurix, Seattle Genetics, Teva Oncology and TG Therapeutics; research funding from Aptose Biosciences, Bristol Myers Squibb, Gilead Sciences and Takeda Oncology; and consultancy and research funding from AstraZeneca, Bayer Oncology, Genentech and Verastem Oncology. J.A.A. has received consulting income from Janssen Biotech, Merck Sharp & Dohme and Dendreon and honoraria for speaker’s fees from Astellas. All other authors declare no competing interests.
